Lung Cancer Clinical Trials in San Antonio

Showing 121-140 of 251 trials

ACTIVE_NOT_RECRUITINGPHASE1/PHASE2< 1 mile

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

NCT05199272

This is a first-in-human open-label Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-00610 given by intravenous infusion in patients with advanced solid malignancies who have progressed on all available standard therapies

Solid TumorClear Cell Renal Cell CarcinomaEpithelial Ovarian Cancer+6 more

23andMe, Inc.141 participantsStarted Dec 2021

Palo Alto, California, United States • Atlanta, Georgia, United States • Detroit, Michigan, United States +10 more locations

TERMINATEDPHASE1< 1 mile

Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

NCT04795713

This will be a Phase 1 Open-label, dose escalation and expansion study of MT-6402 (an Engineered Toxin Body (ETB)) in subjects with advanced solid cancer that expresses PD-L1

Advanced Solid TumorNon-small Cell Lung CancerSquamous Cell Carcinoma of Head and Neck

Molecular Templates, Inc.64 participantsStarted May 2021

Duarte, California, United States • Los Angeles, California, United States • Los Angeles, California, United States +13 more locations

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Lung Cancer Trials in Other Cities

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Milademetan in Advanced/Metastatic Solid Tumors

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

Other Conditions in San Antonio